My role encompasses not only overseeing the strategic growth of the Asian Cancer Institutes but also navigating the complex healthcare landscape in India. The journey involves…
In Conversation
While crucial, Ayushman Bharat is not a standalone solution. India’s strategy should involve a comprehensive approach, including an increase in the overall healthcare budget
In essence, the opportunity lies in aligning chemical production with eco-friendly practices, meeting the sustainability criteria set by major markets. This not only addresses current environmental…
The delicate equilibrium sought by the government, balancing healthcare accessibility, fostering innovation, and promoting value-driven pharmaceutical development, is evident
Our aim is not to become as large as the IQVIAs or Parexels of this world, but to remain a mid-sized CRO that is as global…
The focus is on expanding the market itself rather than gaining market share
We are extremely proud of our ability to ‘turn rocks into diamonds’, which in essence is commercial excellence in action
Leading Indian manufacturers are redefining their roles in global supply chains.
India has an advantage in terms of demographics, digitalisation, and democracy – which encourages and enables creativity and innovation
The Indian pharma industry is very patient-centric, and all its changes ultimately strive to reduce prices, making medicines more affordable and accessible
We are open for business and want to bring the best people, best companies, and best investors into Hong Kong
For pharmaceutical companies, the HK-GBA early access program could serve as a valuable testing ground in GBA for their market launch strategies in mainland China
